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Background
Methotrexate (MTX) is the standard disease modifying
therapy for children with juvenile idiopathic arthritis
(JIA), inducing remission in ~65% of cases. There are cur-
rently no known predictors which classify who will suc-
cessfully respond to MTX therapy nor those who will
remain well following MTX withdrawal. Mechanisms of
MTX action in JIA are at present unclear: genetic and gene
expression profiling would provide novel insights into the
biology of this therapy.
Materials and methods
The SPARKS CHARM (Childhood Arthritis Response to
Medication) prospective cohort of JIA patients have not
received MTX at time of presentation. Peripheral blood
mononuclear cells (PBMC) were taken before MTX ther-
apy and at 6 month follow-up. PMBC from another JIA
cohort who achieved full remission on MTX were taken at
both MTX withdrawal and follow-up. 5 colour flow
cytometry and gene expression profiling (Affymetrix) was
performed on these samples.
Results
There are significant differences in gene expression pro-
files of PBMC of children at time of presentation com-
pared with paired samples at first follow-up. Three
important pathways among those implicated are inflam-
matory cytokines and their signalling pathways, immune
cell antigen presentation and apoptosis.
Conclusion
Gene expression profiling of PBMC provides a valuable
insight into the mode of action of MTX. Upon increasing
the cohort size, detection of genes predicting response to
MTX would then enable appropriate therapy for JIA
patients at time of first presentation in the clinic.
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